Suppr超能文献

直接由患者报告疑似药物不良反应的重要性:患者视角。

The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective.

机构信息

University of Nottingham, Nottingham, UK.

出版信息

Br J Clin Pharmacol. 2011 Nov;72(5):806-22. doi: 10.1111/j.1365-2125.2011.03990.x.

Abstract

AIM

To explore the opinions of patient reporters to the UK Yellow Card Scheme (YCS) on the importance of the scheme.

METHODS

Postal questionnaires were distributed on our behalf to all patient reporters submitting a Yellow Card to the Medicines and Healthcare Regulatory Agency (MHRA) between March and December 2008, with one follow-up reminder to non-responders. Qualitative analysis was undertaken of responses to an open question asking why respondents felt patient reporting was important. This was followed up by telephone interviews with a purposive sample of selected respondents.

RESULTS

There were 1362 evaluable questionnaires returned from 2008 distributed (68%) and 1238 (91%) respondents provided a total of 1802 comments. Twenty-seven interviews were conducted, which supported and expanded the views expressed in the questionnaire. Four main themes emerged, indicating views that the YCS was of importance to pharmacovigilance in general, manufacturers and licensing authorities, patients and the public and health professionals. Reporters viewed the YCS as an important opportunity to describe their experiences for the benefit of others and to contribute to pharmacovigilance. The scheme's independence from health professionals was regarded as important, in part to provide the patient perspective to manufacturers and regulators, but also because of dismissive attitudes and under-reporting by health professionals.

CONCLUSION

Direct patient reporting through the YCS is viewed as important by those who have used the scheme, in order to provide the patient experience for the benefit of pharmacovigilance, as an independent perspective from those of health professionals.

摘要

目的

探讨患者报告者对英国黄卡计划(YCS)的看法,即该计划的重要性。

方法

我们代表药品和保健产品监管局(MHRA)向所有在 2008 年 3 月至 12 月期间向 MHRA 提交黄卡的患者报告者分发了邮寄问卷,并对未回复者进行了一次后续提醒。对一个开放式问题的回答进行了定性分析,该问题询问受访者认为患者报告为何重要。随后,对选定的受访者进行了有针对性的电话访谈。

结果

共发放了 2008 年分发的 1362 份可评估问卷(68%),1238 名(91%)受访者共提供了 1802 条意见。进行了 27 次访谈,这些访谈支持并扩展了问卷中表达的观点。出现了四个主要主题,表明了受访者认为 YCS 对一般药物警戒、制造商和许可当局、患者和公众以及卫生专业人员非常重要。报告者认为 YCS 是一个重要的机会,可以描述他们的经验,为药物警戒做出贡献,为他人谋福利。该计划独立于卫生专业人员被认为很重要,部分原因是向制造商和监管机构提供患者的观点,也因为卫生专业人员的不屑一顾和漏报。

结论

通过 YCS 进行直接的患者报告被那些使用过该计划的人视为重要的,以便为药物警戒提供患者的经验,作为卫生专业人员观点的独立视角。

相似文献

1
The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective.
Br J Clin Pharmacol. 2011 Nov;72(5):806-22. doi: 10.1111/j.1365-2125.2011.03990.x.
3
Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK.
Pharmacoepidemiol Drug Saf. 2011 May;20(5):523-31. doi: 10.1002/pds.2117. Epub 2011 Feb 17.
5
Nonmedical prescriber experiences of training and competence to report adverse drug reactions in the UK.
J Clin Pharm Ther. 2019 Feb;44(1):78-83. doi: 10.1111/jcpt.12756. Epub 2018 Sep 11.
8
Public confidence in ADR identification and their views on ADRreporting: mixed methods study.
Eur J Clin Pharmacol. 2017 Feb;73(2):223-231. doi: 10.1007/s00228-016-2155-5. Epub 2016 Nov 11.
9
Public awareness in Wales of the UK Yellow Card scheme for reporting suspected adverse drug reactions.
Br J Clin Pharmacol. 2021 Aug;87(8):3344-3348. doi: 10.1111/bcp.14726. Epub 2021 Jan 19.
10
Non-medical prescribers and pharmacovigilance: participation, competence and future needs.
Int J Clin Pharm. 2013 Apr;35(2):268-74. doi: 10.1007/s11096-012-9739-7. Epub 2013 Jan 1.

引用本文的文献

5
Accuracy in patient-reported adverse drug reactions and their recognition: a mixed-methods study.
Int J Clin Pharm. 2024 Apr;46(2):401-410. doi: 10.1007/s11096-023-01669-8. Epub 2023 Dec 27.
6
Factors associated with underreporting of adverse drug reactions by patients: a systematic review.
Int J Clin Pharm. 2023 Dec;45(6):1349-1358. doi: 10.1007/s11096-023-01592-y. Epub 2023 May 29.
7
Factors that influence patient and public adverse drug reaction reporting: a systematic review using the theoretical domains framework.
Int J Clin Pharm. 2023 Aug;45(4):801-813. doi: 10.1007/s11096-023-01591-z. Epub 2023 May 29.
9
Thai stakeholders' awareness and perceptions of the patient adverse event reporting system for herbal medicines: a qualitative study.
Int J Clin Pharm. 2023 Apr;45(2):491-501. doi: 10.1007/s11096-022-01533-1. Epub 2023 Feb 6.
10
Active Extraction of Experience of Adverse Drug Reactions in Children.
J Pediatr Pharmacol Ther. 2021;26(4):352-360. doi: 10.5863/1551-6776-26.4.352. Epub 2021 May 19.

本文引用的文献

2
Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK.
Pharmacoepidemiol Drug Saf. 2011 May;20(5):523-31. doi: 10.1002/pds.2117. Epub 2011 Feb 17.
3
Motives for reporting adverse drug reactions by patient-reporters in the Netherlands.
Eur J Clin Pharmacol. 2010 Nov;66(11):1143-50. doi: 10.1007/s00228-010-0865-7. Epub 2010 Jul 24.
4
What motivates patients to report an adverse drug reaction?
Ann Pharmacother. 2010 May;44(5):936-7. doi: 10.1345/aph.1M632. Epub 2010 Apr 13.
5
The missing voice of patients in drug-safety reporting.
N Engl J Med. 2010 Mar 11;362(10):865-9. doi: 10.1056/NEJMp0911494.
6
Attitudes among hospital physicians to the reporting of adverse drug reactions in Sweden.
Eur J Clin Pharmacol. 2009 Jan;65(1):43-6. doi: 10.1007/s00228-008-0564-9. Epub 2008 Sep 30.
8
Patient reporting of suspected adverse drug reactions: a review of published literature and international experience.
Br J Clin Pharmacol. 2007 Feb;63(2):148-56. doi: 10.1111/j.1365-2125.2006.02746.x.
9
Patients' role in reporting adverse drug reactions.
Expert Opin Drug Saf. 2004 Jul;3(4):363-8. doi: 10.1517/14740338.3.4.363.
10
Reasons for reporting adverse drug reactions--some thoughts based on an international review.
Pharmacoepidemiol Drug Saf. 1997 Jan;6(1):21-6. doi: 10.1002/(SICI)1099-1557(199701)6:1<21::AID-PDS259>3.0.CO;2-I.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验